In vitro activity of new antimicrobial agents against glycopeptide-resistant Enterococcus faecium clinical isolates from France between 2006 and 2008

Medecine et Maladies Infectieuses

Volumn 41, Issue 8, 2011, Pages 405-409

  Berenger R ^a   Bourdon, N ^a   Auzou, M ^a   Leclercq, R ^a   Cattoir, V ^a  

^a CHU CÔTE DE NACRE   (France)

Author keywords

E. faecium; GRE; Resistance; Susceptibility; VRE

Indexed keywords

AMPICILLIN; CEFTOBIPROLE; CHLORAMPHENICOL; COTRIMOXAZOLE; DALFOPRISTIN PLUS QUINUPRISTIN; DAPTOMYCIN; DOXYCYCLINE; ERYTHROMYCIN; GENTAMICIN; KANAMYCIN; LEVOFLOXACIN; LINCOMYCIN; LINEZOLID; PRISTINAMYCIN; RIFAMPICIN; TELAVANCIN; TIGECYCLINE;

ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; BACTERIAL GENE; BACTERIAL STRAIN; BACTERIUM ISOLATE; BROTH DILUTION; DISK DIFFUSION; ENTEROCOCCUS FAECIUM; FRANCE; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PULSED FIELD GEL ELECTROPHORESIS; REVIEW; VANB GENE; VANC GENE; VAND GENE; VANE GENE;

ANTI-INFECTIVE AGENTS; DRUG RESISTANCE, BACTERIAL; ENTEROCOCCUS FAECIUM; FRANCE; GLYCOPEPTIDES; HUMANS; TIME FACTORS;

EID: 79961029196     PISSN: 0399077X     EISSN: 17696690     Source Type: Journal    
DOI: 10.1016/j.medmal.2010.12.013     Document Type: Review

References (24)

1. Murray B.E. The life and times of the Enterococcus. Clin Microbiol Rev 1990, 3:46-65.
2. Enquête nationale de prevalence des infections nosocomiales, France, juin 2006. (/enp2006). http://www.invs.sante.fr/.
3. Willems R.J., Bonten M.J. Glycopeptide-resistant enterococci: deciphering virulence, resistance and epidemicity. Curr Opin Infect Dis 2007, 20:384-390.
4. Werner G, Coque TM, Hammerum AM, Hope R, Hryniewicz W, Johnson A, et al. Emergence and spread of vancomycin resistance among enterococci in Europe. Euro Surveill 2008;13(47), PII: 19046.
5. Courvalin P. Vancomycin resistance in gram-positive cocci. Clin Infect Dis 2006, 42(Suppl 1):S25-S34.
6. Bourdon N, Fines-Guyon M, Auzou M, Leclercq R, Cattoir V. Epidemiological and molecular characterization of vancomycin-resistant enterococci (VRE) from France collected between 2006 and 2008, abstr. C2-1899. 49th Intersc. Conf Antimicrob Agents Chemother 2009.
7. Cattoir V., Daurel C. Quelles nouveautés en antibiotherapie ?. Med Mal Infect 2010, 40:135-154.
8. Depardieu F., Perichon B., Courvalin P. Detection of the van alphabet and identification of enterococci and staphylococci at the species level by multiplex PCR. J Clin Microbiol 2004, 42:5857-5860.
9. Comite de l'antibiogramme de la Société française de microbiologie (CA-SFM), recommandations 2010. http://www.sfm.asso.fr/.
10. Comité de l'antibiogramme de la Société française de microbiologie (CA-SFM) Technical recommendations for in vitro susceptibility testing. Clin Microbiol Infect 1996, 2(Suppl. 1):S11-S25.
11. Clinical, Laboratory Standards, Institute Performance standards for antimicrobial susceptibility testing - Eighteenth informational supplement: M100-S18 2008, CLSI, Wayne, PA, USA.
12. Top J., Willems R., Bonten M. Emergence of CC17 Enterococcus faecium: from commensal to hospital-adapted pathogen. FEMS Immunol Med Microbiol 2008, 52:297-308.
13. Cetinkaya Y., Falk P., Mayhall C.G. Vancomycin-resistant enterococci. Clin Microbiol Rev 2000, 13:686-707.
14. Perry C.M., Jarvis B. Linezolid: a review of its use in the management of serious gram-positive infections. Drugs 2001, 61:525-551.
15. Long K.S., Poehlsgaard J., Kehrenberg C., Schwarz S., Vester B. The Cfr rRNA methyltransferase confers resistance to Phenicols, Lincosamides, Oxazolidinones. Pleuromutilins, and Streptogramin A antibiotics. Antimicrob Agents Chemother 2006, 50:2500-2505.
16. Richter S.S., Kealey D.E., Murray C.T., Heilmann K.P., Coffman S.L., Doern G.V. The in vitro activity of daptomycin against Staphylococcus aureus and Enterococcus species. J Antimicrob Chemother 2003, 52:123-127.
17. Rathe M., Kristensen L., Ellermann-Eriksen S., Thomsen M.K., Schumacher H. Vancomycin-resistant Enterococcus spp.: validation of susceptibility testing and in vitro activity of vancomycin, linezolid, tigecycline and daptomycin. APMIS 2010, 118:66-73.
18. Lewis J...S., Owens A., Cadena J., Sabol K., Patterson J.E., Jorgensen J.H. Emergence of daptomycin resistance in Enterococcus faecium during daptomycin therapy. Antimicrob Agents Chemother 2005, 49:1664-1665.
19. Boucher H.W., Sakoulas G. Perspectives on Daptomycin resistance, with emphasis on resistance in Staphylococcus aureus. Clin Infect Dis 2007, 45:601-608.
20. Montero C.I., Stock F., Murray P.R. Mechanisms of resistance to daptomycin in Enterococcus faecium. Antimicrob Agents Chemother 2008, 52:1167-1170.
21. Werner G., Gfrörer S., Fleige C., Witte W., Klare I. Tigecycline-resistant Enterococcus faecalis strain isolated from a German intensive care unit patient. J Antimicrob Chemother 2008, 61:1182-1183.
22. Deshpande L.M., Fritsche T.R., Moet G.J., Biedenbach D.J., Jones R.N. Antimicrobial resistance and molecular epidemiology of vancomycin-resistant enterococci from North America and Europe: a report from the SENTRY antimicrobial surveillance program. Diagn Microbiol Infect Dis 2007, 58:163-170.
23. Singh K.V., Weinstock G.M., Murray B.E. An Enterococcus faecalis ABC homologue (Lsa) is required for the resistance of this species to clindamycin and quinupristin-dalfopristin. Antimicrob Agents Chemother 2002, 46:1845-1850.
24. Krause K.M., Renelli M., Difuntorum S., Wu T.X., Debabov D.V., Benton B.M. In vitro activity of telavancin against resistant gram-positive bacteria. Antimicrob Agents Chemother 2008, 52:2647-2652.